Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 11990 | 7.95 |
09:34 ET | 21067 | 8.022 |
09:36 ET | 109099 | 8.03 |
09:38 ET | 21308 | 8.0473 |
09:39 ET | 19392 | 8.1 |
09:41 ET | 16454 | 8.05 |
09:43 ET | 5145 | 8.08 |
09:45 ET | 11564 | 8.115 |
09:48 ET | 5060 | 8.08 |
09:50 ET | 2270 | 8.09 |
09:52 ET | 5211 | 8.12 |
09:54 ET | 27493 | 8.165 |
09:56 ET | 22340 | 8.1877 |
09:57 ET | 18530 | 8.1901 |
09:59 ET | 56031 | 8.23 |
10:01 ET | 23223 | 8.26 |
10:03 ET | 12849 | 8.225 |
10:06 ET | 9980 | 8.25 |
10:08 ET | 21682 | 8.21 |
10:10 ET | 2734 | 8.24 |
10:12 ET | 6891 | 8.1605 |
10:14 ET | 1734 | 8.18 |
10:15 ET | 7411 | 8.19 |
10:17 ET | 4111 | 8.185 |
10:19 ET | 12884 | 8.16 |
10:21 ET | 12757 | 8.23 |
10:24 ET | 11699 | 8.25 |
10:26 ET | 12362 | 8.22 |
10:28 ET | 36770 | 8.28 |
10:30 ET | 6502 | 8.28 |
10:32 ET | 10354 | 8.3 |
10:33 ET | 18265 | 8.275 |
10:35 ET | 5891 | 8.255 |
10:37 ET | 6820 | 8.235 |
10:39 ET | 200 | 8.22 |
10:42 ET | 7123 | 8.17 |
10:44 ET | 3634 | 8.163 |
10:46 ET | 1001 | 8.164 |
10:48 ET | 12260 | 8.13 |
10:50 ET | 1000 | 8.13 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.5B | -49.1x | --- |
Viking Therapeutics Inc | 5.8B | -61.0x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -12.1x | --- |
Krystal Biotech Inc | 5.2B | 99.3x | --- |
Nuvalent Inc | 4.9B | -31.5x | --- |
BridgeBio Pharma Inc | 4.7B | -7.8x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -49.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.